Jeffrey M. Fish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey M. Fish has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Charles Antzelevitch
Lankenau Institute for Medical Research Wynnewood Pennsylvania USA
2 shared publications Daniel R. Welchons
From the Masonic Medical Research Laboratory, Utica, NY (J.M.F., D.R.W., C.A.); Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea (Y.K.); and National Research Laboratory for Cell Physiology and Department of Physiology, Seoul National University College of Medicine, Seoul, Republic of Korea (S.L., W.H.).
1 shared publication- Suk-Ho Lee
Seoul National University College of Medicine
1 shared publication Won-Kyung Ho
From the Masonic Medical Research Laboratory, Utica, NY (J.M.F., D.R.W., C.A.); Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea (Y.K.); and National Research Laboratory for Cell Physiology and Department of Physiology, Seoul National University College of Medicine, Seoul, Republic of Korea (S.L., W.H.).
1 shared publicationYoung-Sup Kim
From the Masonic Medical Research Laboratory, Utica, NY (J.M.F., D.R.W., C.A.); Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea (Y.K.); and National Research Laboratory for Cell Physiology and Department of Physiology, Seoul National University College of Medicine, Seoul, Republic of Korea (S.L., W.H.).
1 shared publication
Latest Publications
- 21 November 2007
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 19 (3) , 301-308
Cellular Mechanism and Arrhythmogenic Potential of T‐Wave Alternans in the Brugada Syndrome
Introduction: T‐wave alternans (TWA) is characterized by beat to beat alteration in the amplitude, polarity and/or morphology of the electrocardiographic T wave. TWA has been reported in patients with the Brugada syndrome (BS) and is thought to be associated with an increased risk for development of VT/VF. The cellular mechanisms involved are not well‐defined and are the subject of this investigation. Methods: In an experimental model of BS composed of an arterially perfused canine right ventricular wedge preparation pretreated with verapamil (1–7 μM), an agent with sodium and calcium channel blocking activity, we simultaneously recorded transmembrane action potentials from two epicardial and one endocardial site, together with a pseudo‐ECG. At select frequencies, verapamil induced alternans of both the T‐wave amplitude and QT interval. The alternans resulted from either loss of the epicardial action potential dome on alternate beats or concealed phase 2 reentry within the epicardium on alternate beats. Loss of the epicardial action potential dome significantly increased transmural dispersion of repolarization (TDR) when compared with control (18.0 ± 7.8 ms vs. 82.1 ± 16.8 ms, P < 0.001, n = 8). During alternans, TDR was greater in beats displaying a more negative T wave (55.1 ± 45.2 ms vs. 89.8 ± 39.3 ms, P < 0.001, n = 22 data points from 8 preparations). Conclusions: Our data indicate that TWA in an experimental model of the Brugada syndrome is due to alternating loss of the epicardial AP dome and/or concealed phase 2 reentry, both serving to increase TDR and create the substrate for the development VT/VF.
- 21 November 2007
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 19 (3) , 301-308
Cellular Mechanism and Arrhythmogenic Potential of T‐Wave Alternans in the Brugada Syndrome
Introduction: T‐wave alternans (TWA) is characterized by beat to beat alteration in the amplitude, polarity and/or morphology of the electrocardiographic T wave. TWA has been reported in patients with the Brugada syndrome (BS) and is thought to be associated with an increased risk for development of VT/VF. The cellular mechanisms involved are not well‐defined and are the subject of this investigation. Methods: In an experimental model of BS composed of an arterially perfused canine right ventricular wedge preparation pretreated with verapamil (1–7 μM), an agent with sodium and calcium channel blocking activity, we simultaneously recorded transmembrane action potentials from two epicardial and one endocardial site, together with a pseudo‐ECG. At select frequencies, verapamil induced alternans of both the T‐wave amplitude and QT interval. The alternans resulted from either loss of the epicardial action potential dome on alternate beats or concealed phase 2 reentry within the epicardium on alternate beats. Loss of the epicardial action potential dome significantly increased transmural dispersion of repolarization (TDR) when compared with control (18.0 ± 7.8 ms vs. 82.1 ± 16.8 ms, P < 0.001, n = 8). During alternans, TDR was greater in beats displaying a more negative T wave (55.1 ± 45.2 ms vs. 89.8 ± 39.3 ms, P < 0.001, n = 22 data points from 8 preparations). Conclusions: Our data indicate that TWA in an experimental model of the Brugada syndrome is due to alternating loss of the epicardial AP dome and/or concealed phase 2 reentry, both serving to increase TDR and create the substrate for the development VT/VF.
- 21 March 2006
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (11) , 1393-1400
Dimethyl Lithospermate B, an Extract of Danshen, Suppresses Arrhythmogenesis Associated With the Brugada Syndrome
Background— Dimethyl lithospermate B (dmLSB) is an extract of Danshen, a traditional Chinese herbal remedy, which slows inactivation of I Na , leading to increased inward current during the early phases of the action potential (AP). We hypothesized that this action would be antiarrhythmic in the setting of Brugada syndrome. Methods and Results— The Brugada syndrome phenotype was created in canine arterially perfused right ventricular wedge preparations with the use of either terfenadine or verapamil to inhibit I Na and I Ca or pinacidil to activate I K-ATP . AP recordings were simultaneously recorded from epicardial and endocardial sites together with an ECG. Terfenadine, verapamil, and pinacidil each induced all-or-none repolarization at some epicardial sites but not others, leading to ST-segment elevation as well as an increase in both epicardial and transmural dispersions of repolarization (EDR and TDR, respectively) from 12.9±9.6 to 107.0±54.8 ms and from 22.4±8.1 to 82.2±37.4 ms, respectively ( P P Conclusions— Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to implanted cardioverter/defibrillator usage.
- 21 March 2006
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (11) , 1393-1400
Dimethyl Lithospermate B, an Extract of Danshen, Suppresses Arrhythmogenesis Associated With the Brugada Syndrome
Background— Dimethyl lithospermate B (dmLSB) is an extract of Danshen, a traditional Chinese herbal remedy, which slows inactivation of I Na , leading to increased inward current during the early phases of the action potential (AP). We hypothesized that this action would be antiarrhythmic in the setting of Brugada syndrome. Methods and Results— The Brugada syndrome phenotype was created in canine arterially perfused right ventricular wedge preparations with the use of either terfenadine or verapamil to inhibit I Na and I Ca or pinacidil to activate I K-ATP . AP recordings were simultaneously recorded from epicardial and endocardial sites together with an ECG. Terfenadine, verapamil, and pinacidil each induced all-or-none repolarization at some epicardial sites but not others, leading to ST-segment elevation as well as an increase in both epicardial and transmural dispersions of repolarization (EDR and TDR, respectively) from 12.9±9.6 to 107.0±54.8 ms and from 22.4±8.1 to 82.2±37.4 ms, respectively ( P P Conclusions— Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to implanted cardioverter/defibrillator usage.